Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04198740

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface

This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This is an exploratory study. The investigators aim to:

  • Test and perfect a tear sample analysis technique by mass spectrometry with samples collected by Schirmer strips;
  • Obtain the lacrimal fingerprint for various pathologies of the ocular surface, notably different forms of dry eye syndrome, infectious keratitis/conjunctivitis, mucous membrane pemphigoid and allergic conjunctivitis, and establish a normative base for each of them.

During regular clinics at the cornea service of the ophthalmology department of the CHUM (Centre Hospitalier de l'Université de Montréal), the investigators aim to recruit a few hundred patients with various pathologies of the ocular surface, notably different forms of dry eye syndrome, infectious keratitis/conjunctivitis, mucous membrane pemphigoid and allergic conjunctivitis, and collect a sample of their tears via Schirmer strip. A case report form will be completed for each patient, noting known ocular diagnoses and active topical ophthalmic medication. Schirmer strips will be sent in sterile tubes to UQAM (Université du Québec à Montréal)'s department of chemistry for analysis by mass spectrometry.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with healthy corneas or suffering from one of these pathologies:

Dry eye syndrome; Infectious keratitis and/or conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.

Exclusion criteria

  • Patients younger than 18 years old;
  • Patients incapable of giving informed consent.

Treatment and study plan

Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry

Diagnostic Test

During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.

Primary outcomes

  1. To obtain the metabolomic and proteomic fingerprint of the studied ocular surface pathologies

    Time frame: 5 years

    Raw data will be analysed with MarkerView software by Sciex to identify specific over- or under-expressed markers in these ocular pathologies.

Secondary outcomes

  1. To objectify changes in metabolomic and proteomic profile associated with topical treatments taken by participants in this study

    Time frame: 5 years

    Raw data will be analysed with the same software to identify specific changes in proteomic and/or metabolomic expression associated with the topical treatments taken by participants in this study.

Study contacts

Contact information is provided by the study sponsor or research team.

Marie-Catherine Tessier

CONTACT

[email protected]

514-890-8000 ext. 11550

Marie-Claude Robert, MD, M.Sc

CONTACT

[email protected]

514-890-8278

Sponsors and collaborators

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Other

Collaborators

  • Université du Québec a Montréal

Registry information

Acronym: EML-MSO

Important dates

Study start
2020
Primary completion
2034
Study completion
2035
First posted
Dec 13, 2019
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.